Abstract
The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2-overexpressing breast cancer; resistance, however, invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzumab binding epitope, has been implicated as a mechanism of resistance to the antibody. We utilized an in vivo tumor model that overexpresses p95-HER2 and showed it to be resistant to the signaling and antitumor effects of Trastuzumab. We find that both full-length and p95-HER2 interact with the HSP90 chaperone protein and are degraded in tumor cells exposed to HSP90 inhibitors in tissue culture and in vivo. Loss of expression of p95-HER2 is accompanied by downregulation of the phosphoinositide-3 kinase/AKT and extracellular signal-regulated kinase signaling pathways and inhibition of cell proliferation. Chronic administration of HSP90 inhibitors in vivo results in sustained loss of HER2 and p95-HER2 expression and inhibition of AKT activation, together with induction of apoptosis and complete inhibition of tumor growth in Trastuzumab-resistant, p95-HER2-overexpressing models. Thus, p95-HER2 is an HSP90 client protein, the expression and function of which can be effectively suppressed in vivo by HSP90 inhibitors. HSP90 inhibition is therefore a potentially effective therapeutic strategy for p95-HER2-mediated Trastuzumab-resistant breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25: 3234–3244.
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J . (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831.
Basso AD, Solit DB, Munster PN, Rosen N . (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159–1166.
Benezra R, Henke E, Ciarrocchi A, Ruzinova M, Solit D, Rosen N et al. (2005). Induction of complete regressions of oncogene-induced breast tumors in mice. Cold Spring Harb Symp Quant Biol 70: 375–381.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402.
Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240–248.
Clynes RA, Towers TL, Presta LG, Ravetch JV . (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446.
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM et al. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892–4900.
Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E et al. (2004). HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10: 2499–2511.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743.
Gossen M, Bujard H . (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547–5551.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ . (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578–10582.
Hermanto U, Zong CS, Wang LH . (2001). ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20: 7551–7562.
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF, Hynes NE . (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933–8938.
Hudis CA . (2007). Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357: 39–51.
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE . (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210–3223.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–9290.
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M . (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857.
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R et al. (2007). Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25: 5410–5417.
Modi S, Sugarman S, Stopeck AT, Linden H, Ma W, Kersey K et al. (2008). ASCO 2008 Annual Meeting, Chicago, IL.
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J . (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744–4749.
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ et al. (2002). NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347–353.
Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD et al. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451–461.
Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P . (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105–115.
Munster PN, Marchion DC, Basso AD, Rosen N . (2002). Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62: 3132–3137.
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127.
Pederson K, Angelini P, Lao S, Bach-Faig A, Cunninngham MP, Ferrer-Ramon C et al. (2009). A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 29: 3319–3331.
Pegram MD, Lopez A, Konecny G, Slamon DJ . (2000). Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27: 21–25; discussion 92–100.
Rice J, Fadden P, Huang K, Barabasz A, Foley B, Veal J et al. (2008). AACR Annual Meeting San Diego, CA.
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919.
Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J et al. (2006). p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12: 424–431.
Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL et al. (2008). Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589–596.
Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J et al. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628–638.
Shattuck DL, Miller JK, Carraway III KL, Sweeney C . (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471–1477.
She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. (2008). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLOS One 3: e3065.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
Tikhomirov O, Carpenter G . (2003). Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63: 39–43.
Workman P, Burrows F, Neckers L, Rosen N . (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113: 202–216.
Xia W, Liu LH, Ho P, Spector NL . (2004). Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646–653.
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y et al. (2001). Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276: 3702–3708.
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL . (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141.
Yu Q, Geng Y, Sicinski P . (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017–1021.
Acknowledgements
We thank Gail Lewis Phillips and Mark Sliwkowski for providing the Fo5 tumors for this study. We also thank Elisa DeStanchina and Wai Wong for their assistance with animal studies. This work is supported by the National Institute of Health Program Grant P01-CA094060, the Breast Cancer Research Foundation and the generous support of Arlene Taub. S Chandarlapaty is supported by an ASCO Foundation Young Investigator Award.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Chandarlapaty, S., Scaltriti, M., Angelini, P. et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325–334 (2010). https://doi.org/10.1038/onc.2009.337
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.337
Keywords
This article is cited by
-
The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
Cell Death Discovery (2021)
-
A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
Molecular Cancer (2020)
-
The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer
Cell Death & Differentiation (2020)
-
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Molecular Cancer (2018)
-
Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens
Scientific Reports (2017)